Retina Eye Center

05/28/2026

A vitrectomy is a surgical procedure used to treat conditions affecting the retina and the back of the eye. Learn more about what to expect during the procedure, and how it can support your vision: https://brnw.ch/21x2TWl

05/26/2026

A treatment for retinal vein occlusion has been approved for longer-term use in managing macular edema. Learn how this development may help patients maintain more consistent care with fewer treatment switches: https://brnw.ch/21x2PII

The decision lengthens the approved treatment period outlined in the prescribing information and may lessen the need to change therapies for patients who continue to show a lasting response.

05/21/2026

Longer dosing intervals are now available for a treatment used in wet age-related macular degeneration and diabetic macular edema. Learn how this update may help reduce treatment visits and support a more manageable care routine for eligible patients: https://brnw.ch/21x2HbD

Regeneron announced that the FDA has amended the EYLEA HD label after the approval, adding 96-week results from the PULSAR wAMD trial and the PHOTON DME trial.

05/20/2026

Research is now underway studying a potential new treatment for wet age-related macular degeneration. Learn what this study could mean for future approaches to supporting retinal health and patient care: https://brnw.ch/21x2EVu

MALBEC (NCT07440225) is a randomized, double-masked trial evaluating the safety and efficacy of MK-8748 at 2 dose levels versus control (aflibercept 2mg).

05/19/2026

Testimonials like these mean a great deal to our team. We are grateful for the recognition of Dr. Dhaliwal’s professionalism and expertise.

05/14/2026

The Retina Eye Center is committed to advancing care through ongoing research and participation in clinical trials. Our team continually studies the latest advances in vitreoretinal treatments to help bring innovative diagnostic and treatment options to patients.

05/13/2026

At The Retina Eye Center, we provide comprehensive vitreoretinal care focused on each patient’s needs. Our team is dedicated to delivering advanced treatment with compassion and expertise. Learn more: https://brnw.ch/21x2sdk

05/12/2026

A clinical trial for diabetic macular edema is now fully enrolled, studying a long-acting treatment designed to provide extended medication release in the eye. Learn how this research is exploring new ways to support longer-lasting vision care for patients: https://brnw.ch/21x2pYo

The trial will evaluate EC-104 fluocinolone acetonide (FA) extended release for the treatment of diabetic macular edema (DME).

04/30/2026

Diabetic retinopathy is a leading cause of vision loss for adults, but early detection and treatment can make a big difference. Regular eye exams, careful blood sugar control, and specialized retinal care help protect vision from complications like macular edema and retinal bleeding. Learn more: https://brnw.ch/21x24KH

04/28/2026

New treatments for neovascular age-related macular degeneration and diabetic macular edema are helping patients maintain vision with fewer injections. Learn more: https://brnw.ch/21x20t4

Real-world nAMD/DME care highlights durable anti-VEGF options and emerging TKIs and gene therapy to cut injection burden, improve vision, and reduce fluid.

04/23/2026

Geographic atrophy, an advanced form of age-related macular degeneration, now has emerging treatment options, and early detection is key. Experts are exploring how to start therapy safely, monitor progression, and manage potential complications to help patients preserve vision. Learn more: https://brnw.ch/21x1RCc

Three real-world GA cases reveal why early imaging-guided treatment matters, how fast vision can decline, and how to manage CNV risk with anti-VEGF.